GW Pharmaceuticals Plc (GWPH) : Traders are bullish on GW Pharmaceuticals Plc (GWPH) as it has outperformed the S&P 500 by a wide margin of 61.3% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 23.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 23.4% in the last 1 week, and is up 60.44% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 25.26% and the 50-Day Moving Average is 39.01%.The 200 Day SMA reached 70.83%
GW Pharmaceuticals Plc (NASDAQ:GWPH): After opening at $131.54, the stock dipped to an intraday low of $129.26 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $135.16 and the buying power remained strong till the end. The stock closed at $132.73 for the day, a gain of 2.12% for the day session. The total traded volume was 845,719. The stocks close on the previous trading day was $132.73.
GW Pharmaceuticals Plc (GWPH) : Average target price received by GW Pharmaceuticals Plc (GWPH) is $137.33 with an expected standard deviation of $50.19. The most aggressive target on the stock is $182, whereas the most downbeat target is $40. 6 financial analysts are currently covering the stock.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.